ADMS
Income statement / Annual
Last year (2020), Adamas Pharmaceuticals, Inc.'s total revenue was $74.46 M,
an increase of 36.28% from the previous year.
In 2020, Adamas Pharmaceuticals, Inc.'s net income was -$57.40 M.
See Adamas Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$74.46 M
|
$54.64 M
|
$34.05 M
|
$571,000.00
|
$572,000.00
|
$1.92 M
|
$55.85 M
|
$71.10 M
|
$37.47 M
|
| Cost of Revenue |
$2.04 M |
$2.47 M |
$633,000.00 |
$17,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$72.42 M |
$52.17 M |
$33.41 M |
$554,000.00 |
$572,000.00 |
$1.92 M |
$55.85 M |
$71.10 M |
$37.47 M |
| Gross Profit Ratio |
0.97 |
0.95 |
0.98 |
0.97 |
1 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$9.75 M
|
$30.03 M
|
$39.30 M
|
$27.17 M
|
$31.23 M
|
$35.90 M
|
$21.86 M
|
$7.41 M
|
$9.19 M
|
| General & Administrative
Expenses |
$106.84 M
|
$114.37 M
|
$109.14 M
|
$61.31 M
|
$30.33 M
|
$23.46 M
|
$15.47 M
|
$6.67 M
|
$8.33 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$106.84 M
|
$114.37 M
|
$109.14 M
|
$61.31 M
|
$30.33 M
|
$23.46 M
|
$15.47 M
|
$6.67 M
|
$8.33 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$116.59 M |
$144.40 M |
$148.44 M |
$88.48 M |
$61.56 M |
$59.35 M |
$37.33 M |
$14.08 M |
$17.52 M |
| Cost And Expenses |
$118.63 M |
$146.87 M |
$149.07 M |
$88.50 M |
$61.56 M |
$59.35 M |
$37.33 M |
$14.08 M |
$17.52 M |
| Interest Income |
$748,000.00 |
$2.09 M |
$3.12 M |
$1.35 M |
$811,000.00 |
$363,000.00 |
-$917,000.00 |
-$4.82 M |
-$1.91 M |
| Interest Expense |
$13.24 M |
$15.04 M |
$19.09 M |
$4.65 M |
$0.00 |
$0.00 |
$0.00 |
$4.91 M |
$0.00 |
| Depreciation &
Amortization |
$851,000.00
|
$1.21 M
|
$1.46 M
|
$1.19 M
|
$808,000.00
|
$435,000.00
|
$155,000.00
|
$66,000.00
|
$41,000.00
|
| EBITDA |
-$43.31 M
|
-$88.93 M
|
-$110.45 M
|
-$85.38 M
|
-$59.37 M
|
-$56.64 M
|
$17.75 M
|
$57.08 M
|
$18.08 M
|
| EBITDA Ratio |
-0.58 |
-1.63 |
-3.24 |
-149.53 |
-103.78 |
-29.56 |
0.32 |
0.8 |
0.48 |
| Operating Income Ratio
|
-0.59
|
-1.69
|
-3.38
|
-153.99
|
-106.62
|
-29.98
|
0.33
|
0.8
|
0.53
|
| Total Other
Income/Expenses Net |
-$13.24 M
|
-$12.95 M
|
-$15.98 M
|
-$3.29 M
|
$811,000.00
|
$363,000.00
|
-$917,000.00
|
-$4.91 M
|
-$1.91 M
|
| Income Before Tax |
-$57.40 M |
-$105.19 M |
-$131.00 M |
-$91.22 M |
-$60.17 M |
-$57.07 M |
$17.60 M |
$52.11 M |
$18.04 M |
| Income Before Tax Ratio
|
-0.77
|
-1.93
|
-3.85
|
-159.75
|
-105.2
|
-29.79
|
0.32
|
0.73
|
0.48
|
| Income Tax Expense |
$0.00 |
$2.09 M |
$3.12 M |
-$1.73 M |
-$115,000.00 |
-$5.27 M |
$7.37 M |
$1.19 M |
$300,000.00 |
| Net Income |
-$57.40 M |
-$105.19 M |
-$131.00 M |
-$89.49 M |
-$60.06 M |
-$51.80 M |
$10.22 M |
$50.92 M |
$17.74 M |
| Net Income Ratio |
-0.77 |
-1.93 |
-3.85 |
-156.73 |
-105 |
-27.04 |
0.18 |
0.72 |
0.47 |
| EPS |
-1.63 |
-3.8 |
-4.87 |
-3.97 |
-2.77 |
-2.86 |
0.69 |
3.8 |
1.87 |
| EPS Diluted |
-1.63 |
-3.8 |
-4.87 |
-3.97 |
-2.77 |
-2.86 |
0.6 |
3.22 |
1.5 |
| Weighted Average Shares
Out |
$35.17 M
|
$27.68 M
|
$26.89 M
|
$22.56 M
|
$21.71 M
|
$18.11 M
|
$14.84 M
|
$13.41 M
|
$9.51 M
|
| Weighted Average Shares
Out Diluted |
$35.17 M
|
$27.68 M
|
$26.89 M
|
$22.56 M
|
$21.71 M
|
$18.11 M
|
$17.11 M
|
$15.79 M
|
$11.81 M
|
| Link |
|
|
|
|
|
|
|
|
|
